CBD for pain is one of the most searched topics in wellness, and one of the most important to get right. The number of people using CBD for pain-related reasons is substantial, a 2021 Forbes Health survey found pain relief was the most common reason US adults used CBD, and yet the clinical evidence tells a more complicated story than most product marketing suggests.
How CBD Is Thought to Affect Pain
CBD’s potential analgesic effects are believed to operate through several mechanisms simultaneously. CBD acts on TRPV1 receptors, which are pain and temperature sensing receptors involved in the transmission of painful stimuli. It acts at serotonin 5-HT1A receptors, which play a role in pain modulation. It modulates CB1 and CB2 receptor activity in the endocannabinoid system, which has established roles in pain signalling throughout the nervous system and in peripheral tissue. It also has documented anti-inflammatory properties, relevant since inflammation is a driver of pain in many chronic conditions. These multiple potential mechanisms are one reason researchers have been interested in CBD for pain specifically, since pain is itself a complex phenomenon with many contributing pathways.
Where the Evidence Is Strongest
The 2025 update of the Agency for Healthcare Research and Quality’s Living Systematic Review on cannabis and pain, one of the most comprehensive ongoing reviews in this field, found the strongest evidence for cannabinoids in neuropathic pain and pain associated with multiple sclerosis-related spasticity. A systematic review and meta-analysis published in Pharmaceuticals in October 2024 examined clinical trials specifically using CBD without THC for pain. Of the 11 clinical trials meeting their inclusion criteria, 7 reported that CBD treatment produced pain-reducing effects in conditions including osteoarthritis-related pain, chronic or neuropathic pain, bruxism, arthritis, and atopic dermatitis. The same review identified that effects appear to be mediated primarily through TRPV1, 5-HT1A, and CB1 receptor pathways.
University of Rochester research published in November 2025, conducted in collaboration with Harvard Medical School and Boston Children’s Hospital, examined a nano-engineered form of CBD (CBD-IN) designed to cross the blood-brain barrier more effectively. The study found it calmed overactive nerve circuits in brain regions associated with pain without the effect wearing off over time in the study period, a finding the researchers described as potentially opening new doors for treating chronic pain, though this research was preclinical rather than in human patients.
Where the Evidence Is Weakest: A Key Counterpoint
Not all the research points in the same direction. A notable randomised, double-blind, placebo-controlled trial published in PAIN examined CBD as an add-on to paracetamol for chronic osteoarthritis knee pain, administered over a prolonged period at daily oral doses comparable to those used in positive epilepsy trials. The result: no analgesic effect of CBD was observed. The researchers stated that all available evidence from randomised placebo-controlled clinical trials points against a significant analgesic potential of cannabidiol in humans, a conclusion that stands in direct contrast to the positive studies listed above. This discrepancy likely reflects the genuine heterogeneity of pain conditions, dosing variations, and delivery methods across studies, rather than representing a settled answer in either direction.
A 2025 review published in a major pharmacology journal that examined cannabinoids in chronic pain broadly found that while evidence was strongest for neuropathic pain and MS-related spasticity, results for fibromyalgia, osteoarthritis, and musculoskeletal pain remained inconsistent. It found the average pain reduction was modest, often not exceeding 0.5 to 1.0 points on a 10-point scale, and noted that cannabinoids should be considered adjunctive rather than first-line therapy, reserved for carefully selected patients.
CBD vs THC for Pain: An Important Distinction
Much of the strongest evidence for cannabis-based pain relief involves THC alongside CBD, or THC-dominant preparations, rather than CBD alone. Approved medications like Sativex (a roughly 1:1 THC:CBD combination) have clinical evidence for neuropathic pain and MS spasticity. The evidence base for CBD in isolation for pain is smaller and more mixed than the evidence for cannabis formulations that include THC. This matters because many consumers use hemp-derived CBD specifically because it avoids THC, but that same choice may be selecting against the cannabinoid with the strongest pain evidence in many contexts.
Practical Guidance
For acute, severe, or undiagnosed pain, CBD is not an appropriate primary treatment and medical evaluation is always the first step. For chronic pain that is being managed alongside medical care, CBD may provide meaningful adjunctive benefit for some people, particularly for neuropathic pain types, though individual response varies significantly. For pain driven primarily by inflammation, CBD’s anti-inflammatory properties provide a plausible mechanism, and topical CBD applied directly to the affected area may provide more targeted local relief than oral CBD for localised inflammatory pain. Start with a consistent daily oral dose in the 25 to 50 mg range, maintain it for at least four to six weeks before assessing benefit, and keep a simple symptom log to objectively assess whether pain scores are changing.
Frequently Asked Questions
Does CBD actually reduce pain or is it just placebo?
The honest answer is that the clinical evidence is mixed. Some well-designed trials show meaningful pain reduction in specific conditions, particularly neuropathic and osteoarthritis pain. Others, including a rigorous placebo-controlled trial specifically for osteoarthritis knee pain, found no analgesic effect. Individual responses vary considerably. The current scientific consensus is that CBD may help some people with some types of pain, particularly as an adjunct to other treatment, but it is not established as a reliable primary pain treatment across all pain types.
What type of pain does CBD work best for?
Based on the current evidence, neuropathic pain (nerve-related pain from conditions like diabetes, chemotherapy, or nerve injury) and inflammatory pain have the most supporting research. A 2024 systematic review found positive results in 7 of 11 clinical trials covering osteoarthritis pain, neuropathic pain, and arthritis. Evidence for musculoskeletal pain and fibromyalgia is less consistent. CBD alone has a weaker evidence base than THC-containing preparations for most pain types.
Is CBD or THC better for pain relief?
THC has stronger direct evidence for pain relief in many conditions, particularly through its direct binding to CB1 receptors in pain pathways. The most studied cannabinoid medications for pain include both THC and CBD in combination. CBD alone may still provide benefit through anti-inflammatory and other mechanisms, but the evidence base is smaller and more mixed than for THC-containing preparations. For people who cannot or do not want to use THC, CBD remains a reasonable adjunct to try, particularly for inflammatory and neuropathic pain, with realistic expectations.
How much CBD should I take for pain?
Clinical trials for pain have used a wide range of doses. Many studies in the positive category used 25 to 150 mg of CBD per day, often split into two daily doses. A reasonable starting approach is 25 mg twice daily for at least four to six weeks, increasing gradually if there is no response. Taking CBD with a meal containing some fat improves absorption significantly since CBD is fat-soluble. Topical CBD applied directly to a painful area may provide additional localised benefit on top of oral dosing.
Can CBD help with back pain specifically?
Back pain is a broad category that can involve musculoskeletal strain, disc-related nerve compression, inflammatory conditions, and chronic neuropathic components. The evidence for CBD specifically in back pain is limited, with most pain research focusing on osteoarthritis, neuropathic pain, and inflammatory conditions rather than back pain as a discrete category. CBD’s anti-inflammatory and potential analgesic properties provide a plausible mechanism for inflammatory or neuropathic components of back pain, but anyone with significant or persistent back pain should seek medical evaluation to understand the underlying cause before deciding on any supplementary approach.
Why do some people say CBD cured their chronic pain while studies show mixed results?
Several factors contribute to this gap. Individual variability in the endocannabinoid system, pain type, and other biological factors means CBD genuinely works well for some people even when average effects across study populations are modest. Placebo effects in pain research are substantial, sometimes accounting for 30 to 40% of reported improvement in placebo arms of pain trials. People who experience no benefit are less likely to discuss CBD publicly than those who find it helpful, creating a selection bias in anecdotal accounts. And the conditions, doses, and product types people use in real life vary enormously from what is studied in trials.
